1



25 Ranjit Mohan Anjana  $MD<sup>4</sup>$ 

- 26 Moneeza K Siddiqui, PHD,  $^{1,5}$
- 27 Weihua Meng,  $PHD<sup>1,6</sup>$
- 28 Viswanathan Mohan,  $MD<sup>4</sup>$
- 29 Colin N A Palmer<sup>\*</sup>,  $PHD<sup>1</sup>$
- 30  $E_{\text{equal contribution}}$
- 
- <sup>32</sup>Word count: 4,095
- 33 Number of tables and figures: 6
- 34

```
35
35Abstract
```


<sup>38</sup>**Objective:** To investigate the genetic loci influencing NLR and to estimate the heritability and 39 causality of DR with the NLR polygenic risk score (PRS).

<sup>40</sup>**Design:** Genome-wide association study, conditional analysis, Fine and Gray model (FGR),

41 Mendelian Randomization (MR)

<sup>42</sup>**Setting:** Scottish and South Indian populations drawn from population cohorts and electronic medical 43 records.

<sup>44</sup>**Participants:** 29,317 individuals, with a considerable proportion diagnosed with diabetes.

<sup>45</sup>**Measurements:** Effect estimates from GWAS to compute PRS and causal association with DR.

<sup>46</sup>**Results:** Heritability estimates for the Scottish and Indian cohorts were 35.3% and 8.7% respectively.

- 47 The top Single Nucleotide Polymorphisms (SNPs) in the multi-ancestry analysis ( $n=29,317$ ) were
- 48 intergenic: rs1825819 (Chr4:T/C) (Beta= $-0.05$ , p= $2.00 \times 10^{-9}$ ), rs2980871 (Chr8:A/G) (Beta=0.04,
- 49  $p=4.64x10^{-8}$ ), rs2227322 (Chr17:C/G) (Beta=0.07, p=4.12x10<sup>-20</sup>) and rs4808047 (Chr19:T/C) (Beta= -

3



74 several clinical conditions, than a more established marker of inflammation such as C-reactive protein

69 of diabetic retinopathy (DR) was close to 23% and more than 6% experience vision problems.<sup>8</sup>

<sup>70</sup>Increased concentrations of several inflammatory molecules were noted in tissues and vitreous fluids

71 of individuals with DR.<sup>9</sup> Genetic modification of specific inflammatory pathways was shown to

72 arrest the progress of DR.<sup>10</sup> Leukocyte recruitment in DR was found to prolong the inflammatory

73 activity.<sup>11</sup> Neutrophil–Lymphocyte Ratio (NLR) was shown to be more clinically informative for

4

75 (CRP) in interferonopathies.<sup>12</sup> Hence, modeling the joint variations in neutrophils and lymphocytes 76 could be more informative than using them individually as markers of inflammation.<sup>13–17</sup> Indeed, the 77 NLR has been shown to be associated with diabetes and its complications.<sup>18–21</sup> However, no studies <sup>78</sup>have directly investigated the genetic causality of the observed associations. We aimed to identify 79 new genetic loci for NLR with a strict phenotype definition. An allele score for NLR could be more 80 powerful as it entails comprehensive information from multiple genetic loci. We hypothesized that the 81 weighted NLR allele score could be used as an ideal instrumental variable to represent the genetic 82 propensity for a heightened inflammatory response. We therefore performed a genome-wide 83 association study (GWAS) for NLR and used the resulting PRS, both as an exposure and instrument 84 variable to predict and find causal association with DR.

<sup>85</sup>**Methods** 

### <sup>86</sup>**Cohort description and sample selection**

<sup>87</sup>The India-Scotland Partnership for Precision Medicine in Diabetes (INSPIRED) is a collaboration 88 between Dr. Mohan's Diabetes Specialties Centre (DMDSC), and the associated Madras Diabetes 89 Research Foundation (MDRF) at Chennai in South India and the University of Dundee, Scotland.In 90 the discovery phase, we meta-analyzed 3 Scottish cohorts: Genetics of Diabetes Audit and Research 91 in Tayside Scotland (GoDARTS-T2D), Scottish Health Research Register (SHARE), and GoDARTS 92 non-type 2 diabetes controls (GoDARTS controls . However, a small proportion of GoDARTS 93 controls developed diabetes after enrollment. These Scottish cohorts consist of individuals of 94 predominantly white European ancestry. These cohorts and the data linkage strategies used for 95 research have been described previously.<sup>22,23</sup> The findings were replicated in the DMDSC cohort 1 96 and cohort 2. The main difference between the DMDSC cohorts was the sampling strategy employed 97 for genotyping. The participants were selected retrospectively in DMDSC cohort 1. NLR PRS was 98 computed in SHARE using GWAS estimates from the GoDARTS T2D and controls.

5

### <sup>101</sup>**Genotyping**

102 Genotyping methods for the Scottish and Indian cohorts have been described previously.<sup>24</sup> The DNA <sup>103</sup>was extracted from the stored blood plasma. A trained bioinformatician performed the quality control <sup>104</sup>using standard protocols. For all the cohorts, Haplotype Reference Consortium (HRC) was used to 105 infer the missing genotypes. We utilized the GRCh37 assembly (Genome Research Consortium 106 human build 37) to locate SNPs. Affymetrix 6.0, Illumina Human Omni Express, and Broad Institute 107 platforms were used for genotyping GoDARTS. Both, DMDSC and SHARE participants were 108 assayed using the Illumina GSA platform. Alleles with a minimum allele frequency (MAF) greater 109 than 0.05 were considered for GWAS. Additionally, we excluded single nucleotide polymorphism 110 (SNPs) with an info score  $>0.70$  and Hardy-Weinberg equilibrium (HWE)  $< 1 \times 10^{-10}$ . Principal 111 components were computed using Plink Version  $1.9^{25,26}$  We have used STREGA guidelines to report 112 our findings. $27$ 

113

### <sup>114</sup>**Definition of NLR and DR phenotypes**

<sup>115</sup>The Scottish diabetic retinopathy grading scheme was used to ascertain DR status (yes/no) in the 116 Scottish cohort.<sup>28</sup> Details of retinal screening in Tayside were described previously.<sup>29</sup> For the time-117 based Mendelian Randomization (MR) analysis, the first reported DR (any grade from R1 to R4) was 118 considered. For non-DR individuals, the maximum follow-up date was considered as the censoring 119 date. NLR was calculated as the absolute count of neutrophils divided by the absolute count of 120 lymphocytes from the hematology dataset. All values of neutrophils and lymphocytes above and 121 below 5 standard deviations (SD) were removed. The change in NLR above 2.5 from the previous 122 reading was considered and hence excluded. For, individuals having a single NLR reading, values 123 above 5 were excluded. NLR values after diagnosis or treatment for malignancies or within a window 124 period of 31 days after the diagnosis of infectious diseases were discarded. We also did not retain an 125 NLR reading within 28 days after the first reading, assuming that as a case of possible visit for a 126 disease condition.

6

## <sup>127</sup>**Ethics Approval**

- <sup>128</sup>**Tayside, Scotland UK:** Ethical approval for the study was provided by the Tayside Medical Ethics
- <sup>129</sup>Committee (REF:053/04) and the study has been carried out in accordance with the Declaration of

130 Helsinki.

131 **SHARE, Scotland UK:** Ethical approval of the study was provided by the ethics committee SHARE

132 East of Scotland (REF: NHS REC 13/ES/0020).

<sup>133</sup>**DMDSC:** NIHR Global Health Research Unit on Global Diabetes Outcomes Research, Institutional

<sup>134</sup>Ethics Committee of Madras Diabetes Research Foundation, Chennai, India. IRB number

135 IRB00002640. Granted 24<sup>th</sup> August 2017.

### <sup>136</sup>**Statistical Analysis**

#### <sup>137</sup>**GWAS analysis and ascertainment of independent loci**

138 The analytical approaches are shown in Supplementary Figure 1. Continuous variables were 139 summarized as mean/median and categorical variables as frequencies and percentages. GWAS was 140 performed in SNPtest version 2.5.2 with 10 principal components, age, sex, and diabetes status as 141 covariates. Genome-wide Complex Trait Analysis (GCTA) software was used to identify independent 142 genomic loci and genomic inflation was controlled during the computation process.<sup>30</sup> We used the <sup>143</sup>cojo-joint function in the GCTA suite which uses all the SNPs to calculate joint effect size without <sup>144</sup>eliminating less important SNPs from the model. GWAS summary estimates were meta-analyzed 145 with GWAMA (Genome-Wide Association Meta-Analysis) by applying the the genomic control 146 option (-gco) in GWAMA to address inflation and assuming an inverse variance weighted model with a p value significance cut off of  $5x10^{-8}$ .<sup>31</sup> 147

### <sup>148</sup>**Gene enrichment, functional analysis, heritability estimation, and gene network analysis**

<sup>149</sup>Functional Mapping and Annotation of Genome-wide Association Studies (FUMA) was used to 150 create the regional plot, annotation, enrichment statistics, and gene-based tests. We also took 151 annotations from gnomAD (https://gnomad.broadinstitute.org/), UCSC browsers

7

<sup>152</sup>(https://genome.ucsc.edu/), and genecards (https://www.genecards.org/) if the annotations were not 153 available in the FUMA. GeneMANIA was used to understand the co-expression and pathway analysis <sup>154</sup>(https://genemania.org). GeneMANIA predicts weighted gene networks based on well-known genetic 155 databases to visualize gene interactions.<sup>32</sup> Narrow-sense heritability ( $h^2$ ) was estimated using LDAK 156 software. $33$ 

## <sup>157</sup>**PRS estimation**

- 158 PRSice-2 and packages in R version 3.6.1 (The R Foundation for Statistical Computing, Vienna, 159 Austria) were used to generate PRS and perform competing risks analyses, respectively.<sup>34–36</sup> The <sup>160</sup>Clumping and Thresholding method (C+T) in PRSice-2 was utilized for SNP thinning. GoDARTS
- 161 T2D and GoDARTS controls were used as the base data and SHARE as the target data.

### <sup>162</sup>**Competing risks regression and MR analysis**

163 MR and competing risk analyses were performed using allele score as an instrument in the SHARE 164 cohort. Fine and Gray analysis using the riskRegression package with deaths as a competing event 165 adjusting for age, sex, HbA1c, BMI, and creatinine.<sup>37,38</sup> Subsequently, The PRS from the SHARE 166 cohort was used to test the causal relationship between NLR and DR using the one-sample Mendelian 167 randomization (MR) method. For the Mendelian randomization analysis, we experimented with both <sup>168</sup>cross-sectional and time-based models for the same DR phenotypes using R codes, and the *ivtools* 169 package was used for survival MR.<sup>39</sup>

## <sup>170</sup>**Role of the Funding Source**

- 171 The funder had no role in the design, conduct, or analysis of the study or the decision to submit the
- 172 manuscript for publication.

## <sup>173</sup>**Results**

# <sup>174</sup>**Baseline characteristics of the participants**

175 The characteristics of the Scottish discovery cohort (white Europeans,  $n= 21,153$ ) are shown in 176 Supplementary Table 1. Among these, the GoDARTS had the highest sample size. Over 96% of

8

177 individuals had diabetes in the Affymetrix and Illumina sub-cohorts. The median NLR for all the 178 Scottish cohorts was above 2. GoDARTS controls had the lowest median NLR (2.04), and only 7.7% 179 had diabetes. Participants in the GoDARTS were older in comparison to the SHARE cohort. Except 180 for GoDARTS controls, the proportion of males in all other cohorts was above 50%. In the DMDSC <sup>181</sup>(Asian Indians = 8,164), the median NLR (1.93) and the median age was lower (less than 60 years) 182 than the Scottish cohort (Supplementary Table 2). <sup>183</sup>**Discovery Phase in white European cohorts**  <sup>184</sup>Meta-analysis of the 3 Scottish cohorts revealed 150 significant SNPs, most of which were in <sup>185</sup>Chromosome 4 and Chromosome 17 (Supplementary Figures 2-3). Out of these, 128 were from

186 Chromosome 17 and were in high linkage disequilibrium (LD). Only 3 SNPs were independently 187 associated with the NLR trait, of which only one, rs3826331 in chromosome 17, and the rest, <sup>188</sup>rs6841652 and rs16850400 in chromosome 4 (Table 1). Among these, rs3826331 is an intron near the 189 neutrophil gene *PSMD3*, rs6841652 can be mapped either to the *LINCO2513* or *TBC1D1* genetic 190 regions, and the gene corresponding to rs16850400 is yet to be determined. Of the 3 SNPs, the 191 association signal for rs16850400 was suggestive (p=2.39 x 10<sup>-6</sup>). The estimated SNP heritability was 192 35.3% (SD: 0.03). The genomic inflation factor  $(\lambda)$  was within reasonable limits for individual 193 GWAS but was slightly on the higher side for the fixed effects meta-analysis ( $\lambda$ =1.09).

194 Table 1. SNP estimates were identified as conditionally independent using GCTA in the Scottish 195 GWAS meta-analysis

rsid	Genotype MAF Beta			freq bJ		pJ GC	Gene
rs3826331	T/C	0.40	$-0.076$ 0.40		$-0.076$	6.53 x $10^{-14}$	PSMD3
rs6841652	T/C	0.31	$-0.065$ 0.31				$-0.065$ 1.37 x 10 <sup>-9</sup> LINCO2513, TBC1D1
rs16850400	T/C	0.40	0.049	0.60	0.049	$2.39 \times 10^{-6}$	---

9

196 Note. MAF minor allele frequency, freq genotype frequency, bJ beta from the conditional analysis, pJ

<sup>197</sup>GC - p values from the conditional analysis.

## <sup>198</sup>**Replication phase in Asian Indian cohort**

- <sup>199</sup>The DMSDC GWAS plots are shown in Supplementary Figures 5 and 6. The genome-wide search for
- 200 SNPs in the DMDSC cohorts found two highly correlated SNPs in Chromosome 6. Table 2 shows the
- 201 details of these SNPs: rs17330192 (p=1.8 x 10<sup>-8</sup>), and rs139801819 (p=2.4 x10<sup>-8</sup>) were introns found
- 202 near the non-coding region of *LOC102724591* (the RNA gene). Heritability estimated in the Indian
- 203 population was 8.7% (SD: 0.07). During the replication effort, a reversal of SNP effects was noted
- 204 (Table 3), and rs3826331 (T/C) remained statistically significant but with a reversed effect as a trait-
- 205 increasing allele (Beta =0.06, p=1.5 x 10<sup>-6</sup>). We were unable to replicate rs6841652 (p=0.06) and  $206$  rs16850400 (p=0.08) in the DMDSC cohort. Arguably, the MAF was relatively common in both
- 
- 207 ancestries and therefore would not have been the reason for non-replication.

<sup>208</sup>Table 2. Estimates of SNP associations with NLR from the replication analysis in the DMDSC 209 (n=8,164)

rsid	chr: Pos	Genotype	MAF	<b>Beta</b> p			Gene
rs3826331	17:38150492 T/C		0.39		$0.06$ $1.5x\,10^{-6}$	0.77	<i>PSMD3</i>
rs6841652	4:38363262	T/C	0.39	0.02	0.06	$\overline{0}$	LINCO2513, TBC1D1
rs16850400	4:74927915	T/C	0.43	$-0.02$	0.08		$---$

210 Note. MAF minor allele frequency, chr: pos chromosome to position,  $I^2$  - heterogeneity index 211 indicating the percentage of variation across studies

# <sup>212</sup>**Fixed effects trans-ancestry meta-analysis phase**

213 The final sample size for the FE trans-ancestry meta-analysis was 29,317, and the SNP associations 214 are shown in Supplementary Figures 6-7. We identified two novel SNPs in Chromosome 4 and 8: 215 rs1825819 ( $p=2.0x10^{-9}$ ) and rs2980871 ( $p=4.6x10^{-8}$ ) respectively (Table 3). The genomic inflation 216 factor post-correction was 1.07. Regional plots show that both chromosome 17 and chromosome 19

10

217 had many SNPs in high linkage disequilibrium (Supplementary Figures 8-12). Conversely,

218 chromosome 8 and chromosome 4 had very few highly correlated SNPs.

219 In the FE trans-ancestry analysis, all the lead SNPs were found to be in the non-coding regions. 220 Four lead SNPs were found statistically to be significant, of which rs2227322 had the highest trait-221 increasing effect size (0.07,  $p=4.12x10^{-20}$ ). This UTR5 variant was located on chromosome 17 in 222 the *CSF3* gene. This gene was responsible for granulocyte synthesis and also cytokine-related 223 inflammatory responses (https://www.ncbi.nlm.nih.gov/gene/1440). The second notable SNP was 224 rs4808047 on Chromosome 19 (-0.07,  $p=5.93 \times 10^{-12}$ ) in the *EPS15L1* gene and had the lowest <sup>225</sup>MAF (0.28) among the lead SNPs. SNP rs2980871 in Tribbles homolog 1 (*TRIB1*) was another 226 interesting finding. In mouse models, *TRIB1* expression affects hepatic lipid synthesis and 227 glycogenesis.<sup>40</sup> On chromosome 4, rs1825819 with a MAF of 0.38 was found to be associated with 228 NLR  $(-0.05, 2.00 \times 10^{-9})$ . However, there were no known previous phenotype associations or 229 functions identified for this specific SNP, making it a novel locus for NLR. The sentinel SNPs 230 identified in the trans-ancestry meta-analysis generally showed a consistent direction in terms of 231 their effects, except for the SNP rs1825819. The direction of this SNP was trait-increasing in the 232 Broad array and reversed for other cohorts.

Figure 1 shows the significant genes in the trans-ancestry meta-analysis, in the gene-based test, *CLECL1* (chromosome 12), *GSDMA* (chromosome 17)*, CSF3* (chromosome 17)*, PSMD3*  (chromosome 17)*, MED24* (chromosome 17)*, THRA* (chromosome 17)*, CTD-3222D19.2*  (chromosome 19)*, EPS15L1* (chromosome 19)*, CALR3* (chromosome 19)*, CHERP* (chromosome 19)*, CTC429P9.4* (chromosome 19)*, MED26* (chromosome 19)*,* and *SLC35E1* (chromosome 19) were 238 identified. *CLECL1* on chromosome 12 was another important gene that was identified. Among the 13 genes reported in the gene-based test, *GSDMA, CLECL1, CALR3,* and *SLC35E1* did not have any 240 functional relationships with other genes in the network analysis. No gene interaction or pathway 241 information was available for the genes *CTD-3222D19.2* and *CTC429P9*.



<sup>244</sup>Figure 1. Manhattan plot and (left) Q-Q plot (right) corresponding to the gene set analysis from the 245 trans-ancestry GWAS summary (n= 29,317) Note: The SNPs corresponded to 9528 protein coding 246 genes, the genome-wide significance threshold (red dashed line in the plot) was established at  $P =$ 247  $0.05/9528 = 5.248e-6.$ 

248 Table 3. Lead SNPs identified from trans-ancestry inverse variance meta-analysis of Scottish and

249 Indian Cohorts (n=29,317)



250 MAF minor allele frequency, chr: Position chromosome to position,  $I^2$  heterogeneity index indicating

251 the percentage of variation across studies

252 The independent SNPs identified in the discovery set also remained statistically significant in the FE 253 tran-ancestry analysis. Supplementary Figure 13 illustrates the details of the number of SNPs and 254 genes in the important genomic loci in the meta-analysis. Tissue-wise differential gene expression 255 analysis showed that the genes were generally upregulated in the adrenal glands, whole blood, and 256 multiple regions of the brain (Supplementary Figure 14). However, these did not surpass the statistical <sup>257</sup>significance threshold. Gene expression for nine selected significant genes from the gene-based

12

<sup>258</sup>analysis is plotted in Supplementary Figure 15. *PSMD3*, the major gene in our analysis, along with <sup>259</sup>*MED24* and *KLF2,* had a wider gene expression for all the tissues explored in the *GTEx* v8 dataset. <sup>260</sup>*CSF3* had an increased expression level in adipose tissue, fibroblasts, the pituitary, the prostate, the 261 fallopian tubes, and musculoskeletal tissue. *GSMDA* expressions were significant only in two tissues, <sup>262</sup>both relating to skin. Other genes, *CHERP, KLF2, MED24, PSMD3,* and *THRA,* showed heightened 263 expression levels in an overlapping manner for a wide variety of tissues. Significant overlap in gene <sup>264</sup>enrichment was seen in chromosomes 17 and 19 (Supplementary Figure 16). In the gene set analysis, 265 for the 10 leading pathways, only the potassium ion transport pathway remained significant after 266 applying the Bonferroni correction (Supplementary Table 5). 267 We also explored the network of genes closest to the significant SNPs in the trans-ancestry meta-268 analysis (Supplementary Figure 17). The network analysis of significant genes in the trans-ancestry 269 meta-analysis revealed evidence of high co-expression (56.34%), physical interaction (25.35%), and 270 common pathways (13.44%). For the construction of the best-fit PRS, we used 74,377 of 55,333,12 271 variants using the clumping and thresholding  $(C+T)$  method for SNP thinning (Supplementary Figures 272 18-19). The strata plot indicates a dose-response relationship between allele scores and the phenotype,

273 although this was not discernible in the two uppermost quantiles (Figure 2). The gender-wise

274 distribution of NLR and PRS is shown in Supplementary Figure 20.



<sup>277</sup>Figure 2. Strata Plot for the NLR PRS in SHARE. Note: The plot illustrates the change in the 278 computed PRS for NLR on the x-axis and the values of NLR on the y-axis. The blue dot represents 279 the point estimates, and the lines represent the upper and lower 95% confidence intervals for the 280 change in NLR corresponding to the PRS. In general, the NLR phenotype increases with the predicted <sup>281</sup>PRS scores, indicating that PRS can adequately explain the individual variation of the NLR.

# <sup>282</sup>**Competing risks analyses**

283 In the SHARE cohort ( $n=3,892$ ), the Fine and Gray model did not indicate any statistically significant 284 association with DR  $(n=1,610)$  in both adjusted and unadjusted models (Supplementary Table 6). <sup>285</sup>There were 184 competing events, and the mean follow-up time was 4.8 years. The adjusted 286 subhazards for NLR PRS with DR were 1.01 (95% CI: 0.97, 1.06, p=0.48). Thus, PRS for NLR may 287 not be useful for predicting the long-term manifestation of diabetic retinopathy.

# <sup>288</sup>**Mendelian randomization analysis for DR using NLR allele scores**

289 The regression coefficient between the phenotype and PRS was statistically significant at 0.11 290 (p=3.41x10<sup>-15</sup>) (Supplementary Figure 21). The PRS predicted only 1.2% of the NLR variation, which 291 improved to 3.5% after the addition of age and sex (Supplementary Table 7). We analysed 3,561





302 Figure 3. MR analysis of NLR allele score with any DR. Note. Log-linear Logistic linear, TSRI two-303 stage residual inclusion, TSPS two-stage predictor substitution, IV Instrumental Variable, SE standard 304 error, CI confidence interval

15

#### <sup>305</sup>**Discussion**

306 Our study found a divergence in the genetic architecture of NLR between South Asians and white <sup>307</sup>Europeans. South Asian populations are generally underrepresented in genetic studies of NLR, and 308 the present results may cover this gap. In general, white Europeans had a much higher NLR relative 309 to other ancestries.<sup>41</sup> The heritability estimates  $(h^2)$  in our work also reflect this disparity. Our 310 heritability estimates almost matched those in the previous Dutch twins' study.<sup>42</sup> White blood cells 311 are genetically determined; an example is the Duffy-Null polymorphism among the African 312 population arising due to selection pressures. $43$ 

313 Remarkably, NLR was significantly correlated with multiple inflammatory markers such as CRP 314 and IL6, but not platelet-lymphocyte ratio (PLR), implying that the variation of WBC ratios could 315 provide biological insights.<sup>42</sup> Overall, some important genes are associated with white blood cell-316 related traits, but not specifically with the NLR. Chromosome 17q21 contains many genes that exert 317 substantial pleiotropic effects across different WBC subcomponents and is highly expressed in 318 inflammatory disorders such as asthma and diabetes.  $44,45$  Given diabetes and inflammation, there was 319 evidence of *PSMD3* involvement through insulin resistance and receptor tyrosine kinase (RET) 320 signalling, respectively.<sup>46–49</sup> CSF3, MED24, and *PSMD3* genes were reported together to influence 321 neutrophil counts in a Bayesian meta-analysis involving multiple ancestries.<sup>50</sup> Similarly, *GSDMA*, <sup>322</sup>*THRA*, *EPS15L1*, *CALR3*, *CHERP*, and *MED24* were also associated with multiple white blood cell types, including neutrophils and lymphocytes. $45$  Importantly, the rest of the significant genes; <sup>324</sup>*CTC429P9.4*, *CTD3222D19.2,* and *SLC35E1,* do not seem to have a direct link with white blood cell 325 physiology and are therefore novel findings that merit further mechanistic studies. Another novel 326 NLR gene was *CLECL1*, which takes part in the T lymphocyte pathway but is also differentially expressed in clusters of inflammatory conditions such as diabetes mellitus and dyslipidemia.<sup>51</sup>

<sup>328</sup>We replicated rs6841652 of the *LINCO2513/TBC1D gene*. This SNP was also associated with <sup>329</sup>monocyte-lymphocyte ratio and multiple SNPs, that could be traced back to the same genes were  $\sigma$  significant for NLR.<sup>52</sup> We were also able to detect associations with the thyroid hormone receptor 331 gene (*THRA*) that were previously reported for NLR in the Korean population.<sup>53</sup> The complex cross-

16

332 talk between thyroid hormones and immune cells is vital for the proper regulation of inflammatory 333 activity.<sup>54</sup> Most genes from the gene-based set were related in varying degrees, as elicited in the 334 network analysis. Moreover, the gene set analysis overwhelmingly showed affinity for the potassium 335 ion transportation pathway.

336 One of the strengths of the study is that, we did not transform the NLR as opposed to previous studies  $53.55$  As data transformation could rasie concerns of reduced statistical power and ease of beta  $338$  interpretation.<sup>56</sup> A summarized NLR could override possible bias arising from health conditions, 339 outliers, and other unusual deviations from the original phenotype for accurate genome-wide 340 scanning. We further refined the SNP results in each ancestry to identify independent SNPs free from <sup>341</sup>LD. To our knowledge, this is the first study that details the generation of an allelic summary score 342 for NLR and uses it for a causal analysis for DR. We could not replicate the NLR association for DR 343 in the observational study using the PRS.<sup>57–59</sup> The high F statistics for the IV-phenotype relation do 344 not completely eliminate the possibility of bias.<sup>60</sup> It is also possible that the NLR is regulated at a 345 more downstream level by several competing inflammatory pathways or environmental stimuli. <sup>346</sup>Therefore, the current findings may not be sufficient to rule out the role of inflammation in DR. The <sup>347</sup>major limitation was that a substantial proportion of the dataset was used to train the PRSice-2 348 algorithm, leaving a much smaller sample to investigate DR. Due to ancestry differences, PRS and 349 subsequent analysis were conducted only in the Scottish cohorts. Finally, our one sample MR analysis 350 is relatively less powerful compared to a two-sample  $MR<sub>1</sub>$ <sup>61,62</sup> Additional studies are required to 351 understand the genetic mechanisms influencing the NLR between ancestrally diverse populations and 352 subpopulations.

## <sup>353</sup>**Conclusion**

<sup>354</sup>In summary, we report multiple novel intergenic SNPs associated with the NLR in addition to those 355 identified for WBC previously and most of the identified SNPs were in the intergenic regions. There 356 was no evidence to suggest causality between systemic inflammation represented by NLR and DR. In 357 the context of chronic diseases, our findings may provide insights into inflammatory pathways to 358 develop better strategies to deal with inflammatory outcomes.

17

## <sup>359</sup>**Availability of data and materials:**

360 The Scottish and DMDSC datasets are stored electronically in a secure environment. The data is not 361 currently available in the public domain as the participant consent restricts the public sharing of the 362 data. Researchers will require prior approval from the HIC and DMDSC for accessing the related 363 datasets.

364

## <sup>365</sup>**Abbreviations**



18



## <sup>367</sup>**Grant Support:**

368 This research was funded by the National Institute for Health Research (NIHR) (INSPIRED 369 16/136/102) using UK aid from the UK Government to support global health research. The views 370 expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the 371 UK Department of Health and Social Care. Weihua Meng is supported by the Pioneer and Leading 372 Goose R&D Program of Zhejiang 2023 (2023C04049) and the Ningbo International Collaboration 373 Program 2023 (2023H025).

374

# <sup>375</sup>**Corresponding Author**:

19

<sup>\*</sup> 376 <sup>\*</sup> Corresponding author: Professor Colin N A Palmer, University of Dundee, Dundee, UK., Phone:

- 377 +44 (0)1382 383155, Email: c.n.a.palmer@dundee.ac.uk
- 

# <sup>379</sup>**References**

- 380 1. Klein BEK, Knudtson MD, Tsai MY, Klein R. The relation of markers of inflammation and 381 endothelial dysfunction to the prevalence and progression of diabetic retinopathy: Wisconsin 382 epidemiologic study of diabetic retinopathy. Arch Ophthalmol. 2009;127(9):1175–82.
- <sup>383</sup>2. Klein BEK, Myers CE, Howard KP, Klein R. Serum lipids and proliferative diabetic 384 retinopathy and macular edema in persons with long-term type 1 diabetes mellitus: The <sup>385</sup>Wisconsin epidemiologic study of diabetic retinopathy. JAMA Ophthalmol. 2015;133(5):503– 386 10.
- 387 3. Klein R, Klein BEK, Moss SE, Cruickshanks KJ. Relationship of Hyperglycemia to the Long-388 term Incidence and Progression of Diabetic Retinopathy. Arch Intern Med. 389 1994;154(19):2169-78.
- <sup>390</sup>4. Meng W, Shah KP, Pollack S, Toppila I, Hebert HL, McCarthy MI, et al. A genome-wide 391 association study suggests new evidence for an association of the NADPH Oxidase 4 (NOX4) 392 gene with severe diabetic retinopathy in type 2 diabetes. Acta Ophthalmol. 2018;96(7):e811–9.
- 393 5. Pollack S, Igo RP, Jensen RA, Christiansen M, Li X, Cheng CY, et al. Multiethnic genome-394 wide association study of diabetic retinopathy using liability threshold modeling of duration of 395 diabetes and glycemic control. Diabetes. 2019;68(2):441–56.
- <sup>396</sup>6. Choi SW, Mak TSH, O'Reilly PF. Tutorial: a guide to performing polygenic risk score 397 analyses. Nat Protoc. 2020;15:2759–72.
- <sup>398</sup>7. Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis GA, Vogiatzi G, 399 Papaioannou S, et al. The Role of Inflammation in Diabetes: Current Concepts and Future 400 Perspectives. Eur Cardiol. 2019;14(1):50-59.

- 401 8. Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, et al. Global Prevalence of Diabetic
- 402 Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. 403 Ophthalmology. 2021;128(11):1580–91.
- <sup>404</sup>9. Wakabayashi Y, Usui Y, Okunuki Y, Kezuka T, Takeuchi M, Goto H, et al. Correlation of 405 vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy.
- 406 Retina. 2010;30(2):339–44.
- <sup>407</sup>10. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res [Internet]. 408 2011;30(5):343-58.
- <sup>409</sup>11. Noda K, Nakao S, Ishida S, Ishibashi T. Leukocyte Adhesion Molecules in Diabetic 410 Retinopathy. J Ophthalmol. 2012 ;2012:279037.
- 411 12. Kourilovitch M, Galarza–Maldonado C. Could a simple biomarker as neutrophil-to-<sup>412</sup>lymphocyte ratio reflect complex processes orchestrated by neutrophils? J Transl Autoimmun. <sup>413</sup>2022:6;100159.
- <sup>414</sup>13. Anderson BO, Brown JM, Harken AH. Mechanisms of neutrophil-mediated tissue injury. J 415 Surg Res. 1991;51(2):170–9.
- 416 14. Liew PX, Kubes P. The Neutrophil's Role During Health and Disease. Physiol Rev [Internet]. 417 2019;99(2):1223-48.
- 418 15. WW Zhou GY An YPC. Significant difference of neutrophil-lymphocyte ratio between 419 colorectal cancer, adenomatous polyp and healthy people. Eur Rev Med Pharmacol Sci. 420 2017;21(23):5386-91.
- 421 16. Balta S, Celik T, Mikhailidis DP, Ozturk C, Demirkol S, Aparci M, et al. The Relation 422 Between Atherosclerosis and the Neutrophil–Lymphocyte Ratio. Clin Appl Thromb . 423 2016;22(5):405–11.
- <sup>424</sup>17. Liu CC, Ko HJ, Liu WS, Hung CL, Hu KC, Yu LY, et al. Neutrophil-to-lymphocyte ratio as a <sup>425</sup>predictive marker of metabolic syndrome. Medicine (Baltimore). 2019;98(43):e17537.

- <sup>426</sup>18. Ulu SM, Dogan M, Ahsen A, Altug A, Demir K, Acartürk G, et al. Neutrophil-to-Lymphocyte
- 427 Ratio as a Quick and Reliable Predictive Marker to Diagnose the Severity of Diabetic 428 Retinopathy. Diabetes Technol Ther. 2013;15(11):942–7.
- <sup>429</sup>19. Abdullah M. Comparative study on neutrophil-lymphocyte ratio (NLR) among diabetic cases 430 with and without diabetic retinopathy. IJCEO . 2021;7(1):153–6.
- 431 20. Liu J, Liu X, Li Y, Quan J, Wei S, An S, et al. The association of neutrophil to lymphocyte 432 ratio, mean platelet volume, and platelet distribution width with diabetic retinopathy and 433 hephropathy: A meta-analysis. Biosci Rep. 2018;38(3):BSR20180172.
- <sup>434</sup>21. Chittawar S, Dutta D, Qureshi Z, Surana V, Khandare S, Dubey TN. Neutrophil-lymphocyte 435 Ratio is a Novel Reliable Predictor of Nephropathy, Retinopathy, and Coronary Artery Disease 436 in Indians with Type-2 Diabetes. Indian J Endocrinol Metab. 2017;21(6):864-70.
- <sup>437</sup>22. McKinstry B, Sullivan FM, Vasishta S, Armstrong R, Hanley J, Haughney J, et al. Cohort 438 profile: the Scottish Research register SHARE. A register of peopleinterested in research 439 participation linked to NHS data sets. BMJ Open. 2017;7(2):e013351.
- <sup>440</sup>23. Hébert HL, Shepherd B, Milburn K, Veluchamy A, Meng W, Carr F, et al. Cohort profile: 441 Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS). Int J Epidemiol. 442 2018;47(2):380-381j.
- <sup>443</sup>24. Srinivasan S, Liju S, Sathish N, Siddiqui MK, Anjana RM, Pearson ER, et al. Common and <sup>444</sup>distinct genetic architecture of age at diagnosis of diabetes in South Indian and European <sup>445</sup>populations. Diabetes Care. 2023; 46(8):1515-1523.
- 446 25. Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ. Second-generation 447 PLINK: Rising to the challenge of larger and richer datasets. Gigascience. 2015;4(1):s13742– 448 015–0047–8.
- <sup>449</sup>26. Purcell S, Chang C. PLINK 1.9 [Internet]. [cited 2023 Apr 5]. Available from: 450 https://www.cog-genomics.org/plink/1.9/

- <sup>451</sup>27. Little J, Higgins JPT, Ioannidis JPA, Moher D, Gagnon F, Von Elm E, et al. STrengthening
- 452 the REporting of Genetic Association Studies (STREGA)--an extension of the STROBE <sup>453</sup>statement. Genet Epidemiol. 2009 ;33(7):581–98.
- 454 28. Zachariah S, Wykes W, Yorston D. Grading diabetic retinopathy (DR) using the Scottish 455 grading protocol. Community Eye Heal. 2015;28(92):72–3.
- 456 29. Siddiqui MK, Hall C, Cunningham SG, McCrimmon R, Morris A, Leese GP, et al. Using Data 457 to Improve the Management of Diabetes: The Tayside Experience. Diabetes Care. 2022 <sup>458</sup>;45(12):2828–37.
- <sup>459</sup>30. Yang J, Ferreira T, Morris AP, Medland SE, Madden PAF, Heath AC, et al. Conditional and 460 ioint multiple-SNP analysis of GWAS summary statistics identifies additional variants 461 influencing complex traits. Nat Genet . 2012;44(4):369-75.
- <sup>462</sup>31. Mägi R, Morris AP. GWAMA: Software for genome-wide association meta-analysis. BMC 463 Bioinformatics. 2010;11(288).
- <sup>464</sup>32. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, et al. The <sup>465</sup>GeneMANIA prediction server: biological network integration for gene prioritization and 466 predicting gene function. Nucleic Acids Res. 2010;38((Web Server issue)):W214–20.
- <sup>467</sup>33. Speed D, Hemani G, Johnson MR, Balding DJ. Improved Heritability Estimation from 468 Genome-wide SNPs. Am J Hum Genet. 2012;91(6):1011-1021.
- <sup>469</sup>34. Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data. 470 Gigascience. 2019;8(7): giz082.
- <sup>471</sup>35. Team RC. R: A Language and Environment for Statistical Computing [Internet]. Vienna, 472 Austria: R Foundation for Statistical Computing; 2018. Available from: http://www.r-473 project.org.
- <sup>474</sup>36. Gerds AT, Blanche P, Mortensen R, Tollenaar N, Mogensen UB, Ozenne B. Risk Regression 475 Models and Prediction Scores for Survival Analysis with Competing Risks (riskRegression).

23

476 2020.

- 477 37. Austin PC, Lee DS, Fine JP. Introduction to the Analysis of Survival Data in the Presence of <sup>478</sup>Competing Risks. Circulation. 2016;133(6):601–9.
- <sup>479</sup>38. Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for 480 competing risk data. Stat Med . 2017;36(27):4391–400.
- 481 39. Sjolander A, Martinussen T. Instrumental Variable Estimation with the R Package ivtools. <sup>482</sup>Epidemiol Methods. 2019;8(1):20180024.
- <sup>483</sup>40. Ishizuka Y, Nakayama K, Ogawa A, Makishima S, Boonvisut S, Hirao A, et al. TRIB1 <sup>484</sup>downregulates hepatic lipogenesis and glycogenesis via multiple molecular interactions. J Mol 485 Endocrinol . 2014 ;52(2):145–58.
- <sup>486</sup>41. Azab B, Camacho-Rivera M, Taioli E. Average values and racial differences of neutrophil <sup>487</sup>lymphocyte ratio among a nationally representative sample of United States subjects. PLoS 488 One . 2014;9(11):e112361.
- <sup>489</sup>42. Lin BD, Hottenga JJ, Abdellaoui A, Dolan C V, De Geus EJC, Kluft C, et al. Causes of 490 variation in the neutrophil–lymphocyte and platelet–lymphocyte ratios: a twin-family study. 491 Biomark Med. 2016;10(10):1061-1072.
- <sup>492</sup>43. Reich D, Nalls MA, Kao WHL, Akylbekova EL, Tandon A, Patterson N, et al. Reduced <sup>493</sup>neutrophil count in people of African descent is due to a regulatory variant in the Duffy 494 antigen receptor for chemokines gene. PLoS Genet . 2009;5(1):e1000360.
- 495 44. Verlaan DJ, Berlivet S, Hunninghake GM, Madore AM, Larivière M, Moussette S, et al. 496 Allele-specific chromatin remodeling in the ZPBP2/GSDMB/ORMDL3 locus associated with 497 the risk of asthma and autoimmune disease. Am J Hum Genet . 2009 ;85(3):377-93.
- <sup>498</sup>45. Nalls MA, Couper DJ, Tanaka T, van Rooij FJA, Chen MH, Smith A V., et al. Multiple Loci <sup>499</sup>Are Associated with White Blood Cell Phenotypes. PLOS Genet . 2011 ;7(6):e1002113.

- <sup>500</sup>46. Zheng JS, Arnett DK, Parnell LD, Lee YC, Ma Y, Smith CE, et al. Genetic variants at PSMD3 501 interact with dietary fat and carbohydrate to modulate insulin resistance. J Nutr .
- 502 2013;143(3):354-61.
- <sup>503</sup>47. Colaprico A, Olsen C, Bailey MH, Odom GJ, Terkelsen T, Silva TC, et al. Interpreting 504 pathways to discover cancer driver genes with Moonlight. Nat Commun. 2020;11(1):69.
- <sup>505</sup>48. Szilveszter KP, Németh T, Mócsai A. Tyrosine Kinases in Autoimmune and Inflammatory 506 Skin Diseases. Front Immunol . 2019 ;10:1862.
- <sup>507</sup>49. Zheng JS, Arnett DK, Parnell LD, Lee YC, Ma Y, Smith CE, et al. Genetic variants at PSMD3 <sup>508</sup>interact with dietary fat and carbohydrate to modulate insulin resistance. J Nutr. 509 2013;143(3):354-61.
- <sup>510</sup>50. Keller MF, Reiner AP, Okada Y, van Rooij FJA, Johnson AD, Chen MH, et al. Trans-ethnic 511 meta-analysis of white blood cell phenotypes. Hum Mol Genet. 2014 ;23(25):6944-60.
- 512 51. Veroneze R, Corbi SCT, Da Silva BR, De Rocha CS, Maurer-Morelli C V., Orrico SRP, et al. 513 Using association rule mining to jointly detect clinical features and differentially expressed 514 genes related to chronic inflammatory diseases. PLoS One. 2020 ;15(10):e0240269.
- <sup>515</sup>52. Kachuri L, Jeon S, DeWan AT, Metayer C, Ma X, Witte JS, et al. Genetic determinants of 516 blood-cell traits influence susceptibility to childhood acute lymphoblastic leukemia. Am J 517 Hum Genet . 2021;108(10):1823–35.
- 518 53. Park B, Choe E, Kang H, Shin E, Lee S, Won S. Genetic Polymorphisms Associated with the 519 Neutrophil–Lymphocyte Ratio and Their Clinical Implications for Metabolic Risk Factors. J 520 Clin Med. 2018;7(8):204.
- 521 54. Perrotta C, Buldorini M, Assi E, Cazzato D, De Palma C, Clementi E, et al. The Thyroid <sup>522</sup>Hormone Triiodothyronine Controls Macrophage Maturation and Functions: Protective Role 523 during Inflammation. Am J Pathol. 2014;184(1):230–47.
- <sup>524</sup>55. Lin BD, Carnero-Montoro E, Bell JT, Boomsma DI, De Geus EJ, Jansen R, et al. SNP

25

- 525 heritability and effects of genetic variants for neutrophil-to-lymphocyte and platelet-to-
- 526 lymphocyte ratio. J Hum Genet. 2017;62(11):979-88.
- 527 56. Shen X, Rönnegård L. Issues with data transformation in genome-wide association studies for 528 phenotypic variability. F1000Res. 2013;2:200.
- 529 57. Ulu SM, Dogan M, Ahsen A, Altug A, Demir K, Acartürk G, et al. Neutrophil-to-Lymphocyte 530 Ratio as a Quick and Reliable Predictive Marker to Diagnose the Severity of Diabetic 531 Retinopathy. Diabetes Technol Ther. 2013;15(11):942–7.
- <sup>532</sup>58. Binet F, Cagnone G, Crespo-Garcia S, Hata M, Neault M, Dejda A, et al. Neutrophil 533 extracellular traps target senescent vasculature for tissue remodeling in retinopathy. Science . 534 2020;369(6506):eaay5356.
- 535 59. He X, Qi S, Zhang X, Pan J. The relationship between the neutrophil-to-lymphocyte ratio and 536 diabetic retinopathy in adults from the United States: results from the National Health and 537 nutrition examination survey. BMC ophthalmol. 2022 ;22(1):346.
- <sup>538</sup>60. Burgess S, Thompson SG, Chd C, Collaboration G. Avoiding bias from weak instruments in 539 Mendelian randomization studies. Int J Epidemiol. 2011;40(3):755–64.
- <sup>540</sup>61. Burgess S, Scott RA, Timpson NJ, Smith GD, Thompson SG. Using published data in 541 Mendelian randomization: A blueprint for efficient identification of causal risk factors. Eur J 542 Epidemiol . 2015;30(7):543–52.
- <sup>543</sup>62. Burgess S, Timpson NJ, Ebrahim S, Smith GD. Mendelian randomization: where are we now 544 and where are we going? Int J Epidemiol. 2015;44(2):379–88.

545

### <sup>546</sup>**Acknowledgments:**

547 The authors would like to thank all participants in the GoDARTS, SHARE, and DMSDC cohorts. We 548 would also like to thank the Health Informatics Centre (HIC), University of Dundee for providing 549 access to the Scottish Data and staff of MDRF, Chennai.

550

# <sup>551</sup>**Author Contributions:**

- 552 C.N.A.P. and A.L.R were involved in the conceptualisation, analysis, interpretation and manuscript
- 553 writing. A.T.N., M.C., and C.N. were involved in GWAS analysis and heritability estimation. SS
- 554 made a substantial contribution toward ensuring data quality and manuscript revision. M.K.S, V.R.,
- <sup>555</sup>R.M.A., W.M. and V.M. revised the manuscript critically for important intellectual content and
- 556 provided guidance for data analysis. All authors provided approval for manuscript publication.
- 557 C.N.A.P. is the guarantor of this work, had access to the database, and takes full responsibility for the
- 558 integrity of the data, decision to submit and publish the manuscript.

## <sup>560</sup>**Competing interests:**

- 561 None to declare.
- 
- <sup>563</sup>**Supplemental Material**
- 564 Supplementary File 1 Figures
- 565 Supplementary File  $2 Tables$
- 566 STREGA check list